Foot Locker, Inc. (FL)
NYSE: FL · Real-Time Price · USD
24.77
+0.12 (0.49%)
Aug 4, 2025, 4:00 PM - Market closed
Sage Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts that cover Sage Therapeutics stock have a consensus rating of "Hold" and an average price target of $21, which forecasts a -15.22% decrease in the stock price over the next year. The lowest target is $12 and the highest is $28.
Price Target: $21.00 (-15.22%)
Analyst Consensus: Hold
* Price targets were last updated on May 30, 2025.
Analyst Ratings
The average analyst rating for Sage Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Buy | 4 | 3 | 2 | 2 | 2 | 2 |
| Hold | 9 | 8 | 10 | 10 | 10 | 10 |
| Sell | 2 | 2 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 18 | 16 | 15 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Telsey Advisory Group | Telsey Advisory Group | Hold Maintains $24 | Hold | Maintains | $24 | -3.11% | May 30, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | May 29, 2025 |
| Citigroup | Citigroup | Hold Maintains $20 → $24 | Hold | Maintains | $20 → $24 | -3.11% | May 16, 2025 |
| Baird | Baird | Hold Maintains $14 → $24 | Hold | Maintains | $14 → $24 | -3.11% | May 16, 2025 |
| Barclays | Barclays | Buy → Hold Downgrades $14 → $24 | Buy → Hold | Downgrades | $14 → $24 | -3.11% | May 16, 2025 |
Financial Forecast
Revenue This Year
8.06B
from 7.99B
Increased by 0.93%
Revenue Next Year
8.22B
from 8.06B
Increased by 2.01%
EPS This Year
1.19
from 0.13
Increased by 843.44%
EPS Next Year
1.44
from 1.19
Increased by 20.79%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 8.4B | 8.7B | 9.1B |
| Avg | 8.1B | 8.2B | 8.3B |
| Low | 7.3B | 7.5B | 7.6B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 5.7% | 8.3% | 10.3% |
| Avg | 0.9% | 2.0% | 0.9% |
| Low | -8.0% | -7.1% | -8.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.49 | 1.86 | 2.17 |
| Avg | 1.19 | 1.44 | 1.74 |
| Low | 0.74 | 0.69 | 1.23 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1,080.4% | 56.0% | 51.0% |
| Avg | 843.4% | 20.8% | 20.9% |
| Low | 481.9% | -42.4% | -14.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.